Nova Scotia Becomes Sixth Jurisdiction To Implement Biosimilar Switching
Policy Welcomed By Trade And Advocacy Groups
Executive Summary
Citizens enrolled on Nova Scotia’s Pharmacare programs have 12 months to switch to biosimilar versions of certain biologic drugs, including some insulins and medications used to treat Crohn’s disease and rheumatoid arthritis.
You may also be interested in...
Saskatchewan Switching Scheme Boosts Biosimilars In Canada
Saskatchewan has become the latest Canadian province to introduce a biosimilar switching scheme, adding further momentum to the roll-out of similar initiatives across Canada.
Biosimilars ‘Policy Salad’ Setting Back Sector, Canadian Study Says
The Ontario Drug Policy Research Network has released a new study on biosimilar uptake across Canada, where the use of biosimilars is relatively low in comparison to other OECD countries.
Biosimilars ‘Policy Salad’ Setting Back Sector, Canadian Study Says
The Ontario Drug Policy Research Network has released a new study on biosimilar uptake across Canada, where the use of biosimilars is relatively low in comparison to other OECD countries.